ArticlePeerJ2026
Comparison of PCR-based high-resolution melting curve analysis and immunohistochemistry in detecting microsatellite instability in colorectal cancer: a retrospective consistency study.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Microsatellite instability (MS I) is an important biomarker for the prognosis and immunotherapy indications of colorectal cancer (CRC). Traditional detection methods such as immunohistochemistry (I HC) and polymerase chain reaction (PCR)-based capillary electrophoresis (PCR-CE) are widely used, but there are limitations such as strong subjectivity and time-consuming result judgment. This study aims to evaluate the polymerase chain reaction-high-resolution melting curve (PCR-HRM) as a fast, high-throughput MS I detection method. Methods: Tumor samples of 251 CRC patients were analyzed. PCR-HRM and IHC methods are used to evaluate the status of MSI. If the results of PCR-HRM and IHC are inconsistent, the gold standard PCR-CE method is used for confirmation testing. Results: In this study cohort, 20.3% (51/251) of patients had MSI-H or mismatch repair defect (dMMR). PCR-HRM and IHC have excellent consistency, with an overall consistency rate of 99.20% and a Kappa coefficient of 0.971 ( Conclusion: PCR-HRM is a high-precision, low-cost and efficient MSI screening method. It does not require the PCR post-processing required by the traditional method, thus simplifying the workflow. In addition, it also avoids potential problems related to IHC results. Our research shows that PCR-HRM can be a powerful tool to guide the decision-making of colorectal cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.